Loading patent…
AssigneeAcerta Pharma B.V.
InventorsAhmed Hamdy, Wayne Rothbaum, Raquel Izumi, Brian Lannutti, Todd Covey, Roger Ulrich, David M. Johnson, Tjeerd Barf, Allard Kaptein
Estimating the term…
Therapeutic combinations of a phosphoinositide 3-kinase (PI3K) inhibitor, including PI3K inhibitors selective for the γ- and δ-isoforms and selective for both γ- and δ-isoforms (PI3K-γ,δ, PI3K-γ, and PI3K-δ), a Janus kinase-2 (JAK-2) inhibitor, a Bruton's tyrosine kinase (BTK) inhibitor, and/or a B-cell lymphoma-2 (BCL-2) inhibitor are described. In some embodiments, the invention provides therapeutic combinations of a PI3K-δ inhibitor and a BTK inhibitor, a JAK-2 and a BTK inhibitor, and a BCL-2 and BTK inhibitor.
A method of treating a cancer, comprising co-administering, to a mammal in need thereof, one or more compositions comprising therapeutically effective amounts of (1) B-cell lymphoma 2 (BCL-2) inhibitor or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof, and (2) a Bruton's tyrosine kinase (BTK) inhibitor or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.
4-6. (canceled)
10-12. (canceled)
18-83. (canceled)
A composition comprising a BTK inhibitor, wherein the BTK inhibitor is selected from the group consisting of:
Dependencies are inferred from the claim text.